LCI - Lannett Company, Inc.
9.18 0.00 (0.00%)
After hours: 7:10PM EST
| Previous Close | 8.80 |
| Open | 8.86 |
| Bid | 9.27 x 1100 |
| Ask | 9.45 x 900 |
| Day's Range | 8.81 - 9.29 |
| 52 Week Range | 4.33 - 15.52 |
| Volume | 911,132 |
| Avg. Volume | 1,435,637 |
| Market Cap | 370.279M |
| Beta (3Y Monthly) | 2.12 |
| PE Ratio (TTM) | 106.74 |
| EPS (TTM) | 0.09 |
| Earnings Date | Feb 4, 2020 - Feb 10, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.50 |
- Benzinga
Benzinga Pro's Top 5 Stocks To Watch For Wed., Dec. 4, 2019: CRM, WDAY, GPRO, LCI, SPY
Benzinga Pro's Stocks To Watch For Wednesday Salesforce.com (CRM) - Released Q3 EPS and sales results, which beat analyst estimates. The company issued Q4 EPS guidance of $0.54-$0.55, which is below the ...
- MarketWatch
Lannett shares rally on insulin biosimilar trial results
Shares of Lannett Company Inc. rallied 11% in premarket trading after it said a clinical trial for its experimental long-acting insulin biosimilar met the primary endpoints. Lannett and HEC Group are developing a biosimilar version of Sanofi's Lantus, which has long been the French drugmaker's top-selling drug. Mylan and Biocon are also expected to bring a Lantus biosimilar to market in 2020, although the U.S. application process has slowed since the Food and Drug Administration sent two complete response letters with corrective actions. Lannett's stock has jumped 78% year-to-date, compared to the S&P 500 , which is up 24%.
- PR Newswire
Lannett Announces Positive Results From Human Clinical Trial Of Biosimilar Insulin Glargine Versus US Lantus®
Lannett Company, Inc. (NYSE: LCI) today announced positive results from the first human study evaluating insulin glargine that Lannett is developing with its strategic alliance partners within the HEC Group of companies (HEC). Insulin glargine is a long-acting insulin used to treat adults with Type 2 diabetes, as well as adults and pediatric patients with Type 1 diabetes, for the control of high blood sugar.
- Moody's
Lannett Company, Inc. -- Moody's affirms Lannett's B3 CFR and upgrades credit facilities to B2; outlook revised to stable
Moody's Investors Service ("Moody's") affirmed Lannett Company, Inc.'s ("Lannett") B3 Corporate Family Rating and revised the outlook to stable from negative. At the same time, Moody's upgraded the existing senior secured bank credit facilities to B2 from B3 and the Probability of Default Rating (PDR) to B3-PD from Caa1-PD.
- Thomson Reuters StreetEvents
Edited Transcript of LCI earnings conference call or presentation 6-Nov-19 9:30pm GMT
Q1 2020 Lannett Company Inc Earnings Call
- Simply Wall St.
Introducing Lannett Company (NYSE:LCI), The Stock That Tanked 80%
It is a pleasure to report that the Lannett Company, Inc. (NYSE:LCI) is up 32% in the last quarter. But will that heal...
- Zacks
Lannett (LCI) Beats Q1 Earnings and Revenue Estimates
Lannett (LCI) delivered earnings and revenue surprises of 10.00% and 4.88%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Lannett Announces Fiscal 2020 First-Quarter Financial Results
PHILADELPHIA , Nov. 6, 2019 /PRNewswire/ -- Financial and Business Highlights: Net Sales, Profitability Exceeded Expectations Launched First-to-Market Posaconazole Expanded Pipeline with Significant ...
- Zacks
Prothena (PRTA) Reports Narrower-than-Expected Loss in Q3
Prothena (PRTA) posts a narrower Q3 loss while sales surpass estimates.
- Zacks
Radius (RDUS) Q3 Earnings Beat Estimates on Tymlos Strength
Radius (RDUS) reports a narrower-than-expected loss and beats sales estimates in the third quarter of 2019 as Tymlos gains traction.
- Zacks
Mallinckrodt (MNK) Q3 Earnings Beat, Stock Down on Sales Miss
Mallinckrodt (MNK) misses on sales but beats on earnings in the third quarter of 2019.
- Zacks
Bausch (BHC) Beats on Q3 Earnings & Sales, Raises Guidance
Bausch (BHC) beats on sales and earnings in the third quarter and raises annual guidance.
- Zacks
Endo (ENDP) Q3 Earnings & Revenues Beat Estimates, Down Y/Y
Endo (ENDP) reports better-than-expected results for the third quarter as Xiaflex delivers a strong performance.
- Zacks
Lannett (LCI) Dips More Than Broader Markets: What You Should Know
In the latest trading session, Lannett (LCI) closed at $11.88, marking a -1% move from the previous day.
- Zacks
Analysts Estimate Lannett (LCI) to Report a Decline in Earnings: What to Look Out for
Lannett (LCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- PR Newswire
Lannett To Report Fiscal 2020 First-Quarter Financial Results, Host Conference Call On Wednesday, November 6
PHILADELPHIA , Oct. 30, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2020 first quarter on Wednesday, November 6, 2019 , after ...
- Zacks
Lannett (LCI) to Report Q1 Earnings: What's in the Cards?
Lannet's (LCI) fiscal first-quarter 2020 results are likely to reflect strong performance of its anti-psychosis and cardiovascular drugs.
- Zacks
Lannett (LCI) Outpaces Stock Market Gains: What You Should Know
Lannett (LCI) closed the most recent trading day at $12.26, moving +1.16% from the previous trading session.
- Zacks
Is Lannett Co (LCI) Stock Outpacing Its Medical Peers This Year?
Is (LCI) Outperforming Other Medical Stocks This Year?
- Zacks
The Zacks Analyst Blog Highlights: NRG Energy, Lannett Company, Genesis Healthcare, US Foods and Grocery Outlet
The Zacks Analyst Blog Highlights: NRG Energy, Lannett Company, Genesis Healthcare, US Foods and Grocery Outlet
- Zacks
Buy These 5 Defensive Stocks to Counter Market Volatility
Markets have turned volatile due to poor economic data and geopolitical tensions, here are five defensive stocks to boost your portfolio.
- Zacks
Lannett (LCI) Stock Moves -0.9%: What You Should Know
Lannett (LCI) closed at $12.18 in the latest trading session, marking a -0.9% move from the prior day.
- GlobeNewswire
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Lannett Company, LogMeIn, and Mammoth Energy and Encourages Investors to Contact the Firm
NEW YORK, Oct. 04, 2019 -- Bragar Eagel & Squire is investigating certain officers and directors of Lannett Company, Inc. (NYSE: LCI), LogMeIn, Inc. (NASADQ: LOGM), and.
